2021 IPO

Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Stock

Virpax is developing differentiated treatment options that address unmet needs in three multi-billion-dollar markets

Sign up today and learn more about Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Stock

Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our dedication to addressing drug-resistant epilepsy and rare diseases. With a focus on optimizing non-addictive medications, our drug delivery platforms target unmet global needs in markets such as Post Operative Pain, Severe Pain, Post Cancer Pain, and Rare Pediatric Epilepsy, including orphan diseases like Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome. Virpax is at the forefront of providing differentiated solutions for these diverse healthcare challenges.

Funding History

April 2018$1.4M
August 2020$1.0M
January 2021$18.0M
September 2021$40.0M

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo